Sentences with phrase «based cancer testing»

In 1990, ONCOR became the first company to receive FDA approval to market a gene - based cancer testing system for the diagnosis of leukemia and lymphoma.

Passionately pursuing their mission to improve the lives of all patients afflicted with cancer, the people of Ventana discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare.

Not exact matches

For example, labs take DNA samples from patients being tested for cancer and runs tests to detect if mutations typically associated with cancer are present; a diagnostician then examines those genetic mutations and compares them to known instances; finally, based on that information a physician recommends a course of treatment.

In the last of those years, the reporters discovered, the federal government actually spent more on urine - based drug tests than it did on «the four most recommended cancer screenings combined.»

• OncoStem Diagnostics, a Bangalore, India - based developer of tests for personalized cancer treatment planning, raised $ 6 million in funding.

Encinitas - based Okogen has raised $ 10 million to test a drug originally developed for cancer to treat viral conjunctivitis, also known as pink eye.

Prior to joining Oberon, David was Chief Financial Officer and Treasurer at VolitionRx (NYSE MKT: VNRX), a multi-national medical diagnostics company developing simple blood - based tests to accurately diagnose a range of cancers.

Nope, that is why we have an over abundance of children in cancer hospitals being treated on a daily basis because we are being tested by God.

Germany - based biotech companies CureVac and BioNTech are also testing several mRNA - based cancer vaccines in clinical trials.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

The drug was developed by Lawrence - based CritiTech, and the drug - testing and phase I clinical trial were conducted by KU Cancer Center researchers, led by Stephen Williamson, M.D., medical director of Cancer Clinical Trials.

A Berlin - based company called Epigenomics, in partnership with Roche Pharmaceuticals, expects to bring an epigenetic screening test for colon cancer to market by 2008.

Ho and colleagues tested their technique in a rat model of cancer using three FDA - approved chemotherapy nanodrugs, Abraxane ®, Marqibo ® and Onivyde ®, and one experimental platinum - based anti-cancer nanodrug.

A major focus of my research is on developing new technologies, based on hypothesis - driven, targeted mass spectrometry, for relieving this bottleneck to testing potential new blood - based diagnostics for detection of cancer.

«Based on this study, we intend to customise a diagnostic test for each colorectal cancer individual.

«It's very surprising that the nematodes exhibited such a strong binary response to «cancer» versus «no cancer» urine,» says Michael Phillips at Menssana Research, a New Jersey - based company developing diagnostic tests based on people's breath.

«Our odour - based test detected all nine types of cancer we tested.»

Moderna is also doing animal safety tests of a personalized cancer vaccine that would code for immune - activating proteins unique to a person's cancer cells, based on genetic sequencing of their tumor.

This finding is significant in helping to develop personalised diagnostic tests for patients with colorectal cancer based on the genetic changes present in each individual's colon tumour.

The phi test is now available to physicians nationwide through Innovative Diagnostics Laboratory (IDL), a national clinical reference laboratory specializing in personalized blood ‐ based testing to find, understand and treat cancer.

Finally, a Calgary, Alberta — based company, Oncolytics Biotech, is testing a reovirus (an RNA virus often found in human lungs but thought to be nonpathogenic) against several types of cancer, including that of the lung and skin as well as head and neck malignancies.

Based on that assumption, many companies tested PKC inhibitors as drugs to treat cancer, but they didn't work,» said co-senior author Alexandra Newton, PhD, professor of pharmacology at UC San Diego School of Medicine.

In addition to providing insights regarding selection of treatment, this blood test may also prove helpful in assessing the presence of residual disease, recurrence, or relapse and detection of therapy - resistant cancer cells more quickly than conventional tissue - based methods.

«The PSA test is based on the fact that men with higher levels of the PSA protein are more likely to have prostate cancer,» said William Catalona, MD, principal investigator on the Prostate Health Index clinical study and urologist at Northwestern Medicine and director of the Clinical Prostate Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in Febcancer,» said William Catalona, MD, principal investigator on the Prostate Health Index clinical study and urologist at Northwestern Medicine and director of the Clinical Prostate Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in FebCancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in FebCancer Center of Northwestern University, where they began using the phi test on patients in February.

Researchers are even working to develop tests for breast cancer and organ transplant rejection based on the bouquet of a patient's breath.

«The Prostate Health Index is a significant addition to our comprehensive menu of advanced clinical evidence ‐ based blood tests that aid in early cancer detection.»

A scientist from the NIH was one author of the paper describing the discovery, but Myriad Pharmaceuticals, which signed an exclusive licence with the University of Utah where the rest of the research was done, doesn't seem interested in sharing the profits if a breast cancer screening test is devised based on the discovery.

The trial enrolled 398 men with cancer that had not spread outside the prostate gland who were judged to be at high risk of treatment failure, based on standard tests for a number of features of the cancer.

With this context, the new study tested an approach based on the idea that if prostate cancer cells were flooded with testosterone, the cells might be killed by the hormone shock.

To test the notion, the scientists examined DNA from four lung cancer patients, isolating fragments that were 20 - 50 base pairs shorter than the total average size in circulation.

Many countries are currently considering switching from classic Pap tests to primary HPV tests for cervical cancer screening, based on the strong evidence linking cervical abnormalities and infection with certain HPV types, and data suggesting that HPV tests detect more high - grade precancerous lesions.

Researchers at Rice University and the University of Texas MD Anderson Cancer Center have refined and, for the first time, run in vivo tests of a method that may allow nanotube - based probes to locate specific tumors in the body.

A test based on the genetic make - up of the Barrett's lesions could benefit patients through improved diagnosis, giving people at high risk of cancer the best care, and reducing the burden of endoscopy for those at low risk.

Screening for colorectal cancer based on age alone may contribute to both underuse and overuse of the tests among older patients, according to a study by investigators at the University of Michigan and the Veterans Affairs Center for Clinical Management Research.

In fact, the well - known test for prostate cancer, the PSA test (Prostate Specific Antigen), is based on one of the Kallikrein genes, KLK3.

Prostate cancer is has a genetic component but it has until now been impossible to understand how aggressive the cancer might be Now a new multi-national study has discovered the basis of a simple blood test which can predict whether a man is susceptible to aggressive prostate cancer.

In terms of diagnostics, it has six tests on the market, based on research in Iceland, that aim to measure risk of diseases such as heart attack and prostate cancer.

Based on a calculation called the «Risk of Ovarian Cancer Algorithm,» women were divided into three groups: those who should receive another CA125 test one year later (low risk), those who should receive a repeat CA125 in three months (intermediate risk), and those who should receive a transvaginal ultrasound and be referred to a gynecologic oncologist (high risk).

Richards describes how the adoption of some of the standard cancer therapies, such as 5 - Fluorouracil and Interferon, was not based on their passing the validity test Moertel and his colleagues had insisted upon in the case of vitamin C.

The measure aims to make chemical safety reviews more science - based, and includes provisions designed to reduce the use of animals in chemical testing and promote the study of so - called cancer clusters.

Based on the findings of this study, it may be possible to test whether ETC - 159 and other Wnt secretion inhibitors can be used to treat diseases other than cancer.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer cancer cells.

This opens up the exciting possibility of delivering precise treatment for advanced prostate cancer, guided by genomic testing and based on the particular molecular characteristics of patients» tumours.

Professor Widschwendter says: «The data is encouraging since it shows the potential of a blood based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.»

Judge Susan Illston wrote in her opinion that she invalidated the patent, held by the San Diego, California - based company Sequenom, based on several recent rulings, including the Supreme Court's decision denying patent claims on BRCA genes used in cancer risk testing.

Dr. Yang's team has developed the new class of protein - based contrast agents and tested one called ProCA32 that enabled a much earlier detection of liver cancer tumors in mice.

The Houston - based company Nanospectra has licensed the treatment, and company president Don Payne expects to begin testing it on cancer patients within a year.

Professor Paul Pharoah, professor of cancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer epidemiology at the Cancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestCancer Research UK Cambridge Institute, said: «Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatestcancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk.

Now, as a result of 10 years work, Huang and her team have created a cervical cancer screening technique that, based on an analysis of a very large dataset, has the potential to perform as well or better than human interpretation on other traditional screening results, such as Pap tests and HPV tests — at a much lower cost.

Platinum - based therapies are being tested in clinical trials for triple - negative breast cancer, and evaluation of tumor - infiltrating lymphocytes is an important factor in determining response to this treatment.